Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability

Cell Death and Differentiation

Volumn 10, Issue 6, 2003, Pages 740-748

  Luke, J J ^a   van de Wetering, C I ^a   Knudson, C M ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Apoptosis; Bax; Bcl 2; Chromosomal instability; Oncogenesis

Indexed keywords

DNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANEUPLOIDY; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DNA CONTENT; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC STABILITY; MOUSE; NONHUMAN; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; T LYMPHOCYTE; THYMUS LYMPHOMA; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; LYMPHOMA; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS MUSCULUS;

EID: 0037945540     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401233     Document Type: Article

References (67)

1. Gross A, McDonnell JM and Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899
2. Adams JM and Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26: 61
3. Harris MH and Thompson CB (2000) The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7: 1182
4. MacCarthy-Morrogh L, Mouzakiti A, Townsend P, Brimmell M and Packham G (1999) Bcl-2-related proteins and cancer. Biochem. Soc. Trans. 27: 785
5. Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacCregor GR, Thompson CB and Korsmeyer SJ (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727
6. Zong WX, Lindsten T, Ross AJ, MacGregor GR and Thompson CB (2001) BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes & Dev. 15: 1481
7. Cheng E, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T and Korsmeyer SJ (2001) BCL-2, BCL-X-L sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8: 705
8. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL and Korsmeyer SJ (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899
9. Cleary ML and Sklar J (1985) Nucleotide sequence of a t(14:18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. USA 82: 7439
10. Tsujimoto Y, Gorham J, Cossman J, Jaffe E and Croce CM (1985) The t(14:18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390
11. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP and Korsmeyer SJ (1989) bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57: 79
12. Linette GP, Hess JL, Sentman CL and Korsmeyer SJ (1995) Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice. Blood 86: 1255
13. Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293
14. Sidransky D and Hollstein M (1996) Clinical implications of the p53 gene. Ann. Rev. Med. 47: 285
15. Yin CY, Knudson CM, Korsmeyer SJ and Van Dyke T (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637
16. Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T, Korsmeyer SJ and Green JE (1999) Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J., 18: 2692
17. Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290: 989
18. Eischen CM, Roussel MF, Korsmeyer SJ and Cleveland JL (2001) Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cel. Biol. 21: 7653
19. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC and Perucho M (1997) Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967
20. LeBlanc JLD, Vargolomeev E, Totpal K, Morlan J, Schow, P, Fong S, Schwall R, Sinicropi D and Ashkenazi A (2002) Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8: 274
21. Murphy KL, Kittrell FS, Gay JP, Jager R, Medina D and Rosen JM (1999) Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. Oncogene 18: 6597
22. de la Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van Dyke T, Kahn A and Perret C (1999) Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res. 59: 5017
23. Meterissian SH, Kontogiannea M, Al-Sowaidi M, Linjawi A, Halwani F, Jamison B and Edwardes M (2001) Bcl-2 is a useful prognostic marker in Dukes'B colon cancer. Ann. Surg. Oncol. 8: 533
24. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, Zupi G and Mottolese M (1999) Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and Bcl-2. Int. J. Cancer 84: 545
25. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S and Grizzle WE (1997) Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int. J. Cancer 74: 346
26. Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B and Schmid KW (1995) Immunohistochemically detectable bcl-2 expression in colorectal carcinoma - correlation with tumour stage and patient survival. Br. J. Cancer 72: 981
27. Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I, Biddolph S, Tsiotos P, Mortensen N, Gatter KC and Harris AL (1998) Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. Br. J. Cancer 77: 1864
28. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Difronzo G, Rilke F and Veronesi U (1994) The bcl-2 protein - a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Nat. Cancer Inst. 86: 499
29. Knudson CM, Johnson GM, Lin Y and Korsmeyer SJ (2001) Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res. 61: 659
30. Hogarth LA and Hall AG (1999) Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood 93: 2671
31. Bairey O, Zimra Y, Shaklai M, Okon E and Rabizadeh E (1999) Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin. Cancer Res. 5: 2860
32. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57
33. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT and Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1
34. McCurrach ME, Connor TMF, Knudson CM, Korsmeyer SJ and Lowe SW (1997) Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA, 94: 2345
35. Yamamoto H, Itoh F, Fukushima H, Adachi Y, Itoh H, Hinoda Y and Imai K (1999) Frequent Bax frameshift mutations in gastric cancer with high but not low microsatellite instability. J. Exp. Clin. Cancer Res. 18: 103
36. Meijerink JPP, Mensink EJBM, Wang K, Sedlak TW, Sloetjes AW, Dewitte T, Waksman G and Korsmeyer SJ (1998) Hematopoietic malignancies demonstrate loss-of-function mutations of BAX Blood 91: 2991
37. Gil J, Yamamoto H, Zapata JM, Reed JC and Perucho M (1999) Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res. 59: 2034
38. Tai YT, Lee S, Niloff E, Weisman C, Strobel T and Cannistra SA (1998) BAX protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol. 16: 2583
39. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55: 4471
40. Xie X, De Angelis P, Clausen OPF and Boysen M (1999) Prognostic significance of proliferative and apoptotic markers in oral tongue squamous cell carcinomas. Oral Oncol. 35: 502
41. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dorken B and Daniel PT (2001) Analysis of p53/BAX/p16 (ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16 (nk4a/CDKN2) identifies patients with good prognosis. J. Clin. Oncol. 19: 2272
42. Ong YL, McMullin MF, Bailie KEM, Lappin TRJ, Jones FGC and Irvine AE (2000) High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br. J. Haematol. 111: 182
43. Brady HJ, Gil-Gomez G, Kirberg J and Berns AJ (1996) Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J. 15: 6991
44. Linette GP, Li Y, Roth KA and Korsmeyer SJ (1996) Crosstalk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. Proc. Natl. Acad. Sci. USA 93: 9545
45. O'Reilly LA, Huang DC and Strasser A (1996) The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 15: 6979
46. O'Reilly LA, Harris AW and Strasser A (1997) bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors. Int. Immunol. 9: 1291
47. Huang DC, O'Reilly LA, Strasser A and Cory S (1997) The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J. 16: 4628
48. Lengauer C, Kinzler KW and Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643
49. Lengauer C, Kinzler KW and Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386: 623
50. Wright EG (1999) Inherited and inducible chromosomal instability: a fragile bridge between genome integrity mechanisms and tumorigenesis. J. Pathol. 187: 19
51. Joenje H and Patel KJ (2001) The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2: 446
52. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ (1997) Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139: 1281
53. Youssoufian H (1996) Cytoplasmic localization of fac is essential for the correction of a prerepair defect in Fanconi anemia group c cells. J. Clin. Invest. 97: 2003
54. Rathbun RK, Christianson TA, Faulkner GR, Jones G, Keeble W, O'Dwyer M and Bagby GC (2000) Interferon-gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood 96: 4204
55. Rathbun RK, Faulkner GR, Ostroski MH, Christianson TA, Hughes G, Jones G, Cahn R, Maziarz R, Royle G, Keeble W, Heinrich MC, Grompe M, Tower TA and Bagby GC (1997) Inactivation of the Fanconi-anemia group c gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 90: 974
56. Haneline LS, Broxmeyer HE, Cooper S, Hangoc G, Carreau M, Buchwald M and Clapp DW (1998) Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from fac(-/-) mice. Blood 91: 4092
57. Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ and Buchwald M (2001) Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nat. Med. 7: 816
58. Kampranis SC, Damianova R, Atallah M, Toby G, Kondi G, Tsichlis PN and Makris AM (2000) A novel plant glutathione S-transferase/peroxidase suppresses Bax lethality in yeast. J. Biol. Chem. 275: 29207
59. Limoli CL, Hartmann A, Shephard L, Yang CR, Boothman DA, Bartholomew J and Morgan WF (1998) Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity. Cancer Res. 58: 3712
60. Limoli CL, Kaplan MI, Corcoran J, Meyers M, Boothman DA and Morgan WF (1997) Chromosomal instability and its relationship to other end points of genomic instability. Cancer Res. 57: 5557
61. Nacht M and Jacks T (1998) V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ. 9: 131
62. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S and Papaioannou VE (1992) Rag-1-deficient mice have no mature B and T lymphocytes. Cell 68: 869
63. Uedo E, Kurebayashi S, Sakaue M, Backlund M, Koller B and Jetten AM (2002) High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor ROR γ. Cancer Res. 62: 901
64. Cerhan JR, Wallace RB, Folsom AR, Potter JD, Sellers TA, Zheng W and Lutz CT (1997) Medical history risk factors for non-Hodgkins lymphoma in older women. J. Nat. Cancer Ins. 89: 314
65. Knudson CM and Korsmeyer SJ (1997) Bcl-2 and Bax function independently to regulate cell death. Nat. Genet. 16: 358
66. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847
67. Krishan A (1990) Rapid DNA content analysis by the propidium iodide-hypotonic citrate method. Methods Cell Biol. 33: 121